News Pharma collaborates to improve chances of NICE backing Duche... Project will initially focus on DMD but could benefit other rare diseases
Views & Analysis Budget impact and cost effectiveness: alternatives to NICE a... A new way to capture when drugs are ‘cost effective’ but not ‘affordable’ looks set to be introduced in England.
Articles NICE and Highly Specialised Technologies: three years on Leela Barham examines the process for the appraisal of Highly Specialised Technologies.
Views & Analysis Funding rare disease treatments in the UK – navigating the l... With the appraisal process for highly specialised treatments in the UK described by one NHS insider as 'impenetrable', and The MPS Society's (The Society for Mucopolysaccharide Diseases) recent
Oncology Takeda’s Innovent deal bears fruit, with Teresa Bitetti and ... Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
